Neuralgap Drug Discovery
Unifying dynamic ligand-receptor interactions and structural data through Neuralgap's Multi-Unimodal approach
Our state-of-the-art Multi-Unimodal Architecture rethinks drug discovery by analyzing multiple types of molecular interactions simultaneously.
By processing multiple modalities – everything from structural properties to dynamic binding patterns – we are creating a framework for pharma startups to create more refined, ‘context-aware’ drug candidates.
Adaptability
The MUM architecture forms the base of Genesys, and its ability to learn without distribution shifts enables new modalities to be bolted on.
Discovery Efficiency
Multiple ‘versions’ of the models can be created, from very heavy to light weight depending on the stage of the pipeline.
Unified Processing
Adaptive Learning
Intelligent Scaling
Manage virtual screening, from QSAR to Struture based screening to Molecular Dynamics from a single platform.
Bioforager uses the latest AI Agent workflows to guide, iterate, and analyse your results.
Bioforager is also host to the ground-breaking Genesys engine that allows you to get state-of-the-art results, even on specific, rare protiens.